SCHEMBL4183483

SCHEMBL4183483

COc1cccc(C2CCN(C(=O)c3ccc(C)c(NS(C)(=O)=O)c3)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 2/20 0.52
HSD11B1 P28845 2/20 0.48
USP5 P45974 1/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TSHR P16473 1/20 0.48
MGLL Q99685 1/20 0.47
MYC P01106 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
HCRTR2 O43614 1/20 0.45
PROKR1 Q8TCW9 1/20 0.45
PARP14 Q460N5 2/20 0.45
PARP10 Q53GL7 2/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4165892 0.89 FASN (0.59) FASNHSD11B1ALDH1A1LMNATSHR
SCHEMBL4182310 0.87 FASN (0.58) FASNHSD11B1ALDH1A1KDM4ECA12
SCHEMBL4177027 0.86 FASN (0.54) FASNHSD11B1ALDH1A1TSHRMGLL
SCHEMBL4183758 0.86 FASN (0.54) FASNHSD11B1USP5MGLLCA12
SCHEMBL4177513 0.86 FASN (0.54) FASNHSD11B1ALDH1A1MGLLCA12
SCHEMBL4175591 0.86 FASN (0.56) FASN
SCHEMBL4175616 0.85 FASN (0.53) FASNHSD11B1ALDH1A1MGLLCA12
SCHEMBL4172334 0.84 FASN (0.58) FASNLMNAKDM4E
SCHEMBL4170238 0.84 FASN (0.66) FASN
SCHEMBL4781999 0.84 FASN (0.52) FASNHSD11B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 US claimed
WO-2008075070-A1 SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS ASTRAZENECA AB (SE) 2008-06-26 WO claimed
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 US disclosed
WO-2008075070-A1 SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS ASTRAZENECA AB (SE) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105305-A1 Therapeutic Agents - 550 FABP4, GPR119, FASN FASN 3/4885HSD11B1 126/4885USP5 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.